Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:NBIX
NasdaqGS:NBIXBiotechs

3 Companies That May Be Priced Below Their Estimated Value

As the U.S. stock market rebounds from a recent tech sector downturn, major indices like the Nasdaq, Dow Jones Industrial Average, and S&P 500 have shown resilience despite ongoing economic uncertainties such as the government shutdown and trade policy debates. In this fluctuating environment, identifying stocks that may be undervalued can offer potential opportunities for investors seeking to capitalize on discrepancies between current prices and estimated intrinsic values.
NYSE:TOST
NYSE:TOSTDiversified Financial

Credo Technology Group Holding And 2 More Top Growth Stocks With Insider Stake

As the U.S. stock market rebounds from a recent tech rout, with major indexes closing higher amid ongoing economic uncertainties, investors are increasingly attentive to growth companies that demonstrate resilience and potential for long-term success. In this context, stocks like Credo Technology Group Holding stand out not only for their growth prospects but also for their high insider ownership, which can be an indicator of strong internal confidence and alignment with shareholder interests.
NasdaqCM:CORT
NasdaqCM:CORTPharmaceuticals

Corcept Therapeutics (CORT): Margin Dip to 18.4% Challenges Recent Bullish Narratives

Corcept Therapeutics (CORT) posted average earnings growth of 5.5% annually over the past five years, with a 5.6% uptick in the most recent year. Revenue is forecast to climb sharply at 28.2% per year, far outpacing the projected 10.4% growth rate for the US market. While net profit margins have dipped to 18.4% from last year’s 21.9%, high earnings quality and robust growth expectations continue to fuel positive investor sentiment despite a premium valuation. See our full analysis for Corcept...
NasdaqGS:IBRX
NasdaqGS:IBRXBiotechs

ImmunityBio (IBRX): Losses Worsen While 54.9% Projected Revenue Growth Tests Bullish Narratives

ImmunityBio (IBRX) reported another unprofitable period, with losses accelerating at a 15% annual rate over the past five years and net profit margins failing to show improvement. Forecasts suggest the company will remain unprofitable for at least the next three years. However, revenue is projected to surge by 54.9% per year, far outpacing the broader US market's 10.4% average growth rate. Investors now face the challenge of weighing a robust revenue outlook against ongoing losses and high...
NYSE:AIZ
NYSE:AIZInsurance

Assurant (AIZ): Margin Compression Challenges Bullish Community Narratives Despite Fair Value Discount

Assurant (AIZ) posted a net profit margin of 5.8%, down from last year's 6.9%, while earnings have grown at an average rate of 9.7% annually over the past five years. Market forecasts suggest earnings and revenue will continue to rise at 11.9% and 4.1% per year respectively, both trailing the broader US market’s growth outlook. Shares currently trade at a P/E of 15.4x, above industry and peer averages, but the price remains below an internally estimated fair value, putting the spotlight on...
NYSE:CNX
NYSE:CNXOil and Gas

Has the Recent Jump in Gas Demand Forecasts Changed the Outlook for CNX Resources in 2025?

If you’ve ever wondered whether CNX Resources is a bargain or priced for perfection, you’re not alone. Figuring that out is where smart investing starts. Despite a tough year with the stock down 8.3% over the last 12 months, short-term performance is turning around, up 7.1% just this week. Recent news has focused on increased natural gas demand forecasts and shifting analyst sentiment, which are fueling renewed interest in energy stocks like CNX. Momentum from policy changes around domestic...